Table 1

Protocol schedule of procedures for the ACT4FCD study

	Screening	Baseline (T0)	2 months (T1)	4 months (T2)	6 months (T3)
Enrolment
Consent to contact obtained by clinical staff in DMC, CNC or NPC	x
Informed consent	x
Contacted by RA to arrange screening interview	x
Screening
Diagnostic criteria for FCD	x
Risk Assessment	x
Demographics	x
Comorbidities	x
Medications	x
PHQ-9	x
GAD-7	x
Randomisation allocation		x
Interventions		ACT+TAU	Intervention completed
Assessments
AAQ-II		x	x	x	X
MMQ		x	x	x	X
WHODAS 2.0		x	x	x	X
EQ-5F-5L		x	x	x	X
PHQ-9		x	x	x	X
GAD-7		x	x	x	X
AD-SUS		x			X
ICECAP-A		x	x	x	X
CGI-I					X
Likert 5-point satisfaction scale				x
AEs/SAEs		x	x	x	X
Qualitative interviews
Informed consent for qualitative interview (select participants)		x	x
Qualitative interviews with select sample of participants		x	x

AAQ-II, Acceptance and Action Questionnaire II; ACT4FCD, Acceptance and Commitment Therapy for Functional Cognitive Disorder; AD-SUS, Adult Service Use Schedule; AEs, adverse events; CNC, cognitive neurology clinic; DMC, diagnostic memory clinic; EQ-5F-5L, EuroQol 5-Dimension-5-Level; GAD-7, Generalised Anxiety Disorder 7; GCI-I, Clinical Global Impression-Improvement; ICECAP-A, ICEpop CAPability measure for Adults; MMQ, Multifactorial Memory Questionnaire; NPC, neuropsychiatry clinic; PHQ-9, 9-question Patient Health Questionnaire; RA, Research Assistant; SAE, serious adverse event; TAU, treatment as usual; WHODAS 2.0, WHO Disability Assessment Schedule.